TrialBritish journal of haematology2022

Zanubrutinib for treatment-naïve and relapsed/refractory chronic lymphocytic leukaemia: long-term follow-up of the phase I/II AU-003 study.

Gavin Cull et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.